Global medtech contract research organisation (CRO) Avania has acquired Spanish counterpart Anagram for an undisclosed fee.
Headquartered in Barcelona, Anagram is one of the leading medtech CROs in the Iberian Peninsula, across Europe and beyond.
It was founded in 1998 and is focused on cardiology, oncology, and neurology therapeutic areas.
Its study locations include the US, UK, Spain, Netherlands, France and Germany.
The deal will enable Avania to increase its CRO business in Spain and provide greater access to what it sees as a growing medtech country.
“It will support cross-sell opportunities by adding scale and will eliminate reliance on current outsourcing partners”, the company said.
Jason Monteleone, president and CEO of Avania, said: “The addition of Anagram furthers our vision of becoming a trusted global partner for the MedTech community, advancing innovations from bench to bedside and improving patient outcomes globally.
“It will provide us with a significant footprint in Spain and Southern Europe and further strengthen our cardiovascular and neurology franchises while expanding our oncology capabilities.”
Avania’s focus is on medical devices, diagnostics/IVDs, and digital health.
